341 related articles for article (PubMed ID: 21519165)
1. [Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].
Lee JE; Yoon NR; Kim JD; Song MJ; Kwon JH; Bae SH; Choi JY; Jeong SW; Yoon SK
Korean J Gastroenterol; 2011 Mar; 57(3):173-9. PubMed ID: 21519165
[TBL] [Abstract][Full Text] [Related]
2. [Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].
Kim CH; Park BD; Lee JW; Kim YS; Jeong S; Lee DH; Kim HG; Shin YW; Kwon KS; Lee JI
Korean J Hepatol; 2009 Mar; 15(1):70-9. PubMed ID: 19346787
[TBL] [Abstract][Full Text] [Related]
3. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
4. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
[TBL] [Abstract][Full Text] [Related]
5. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
6. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.
Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
Int J Infect Dis; 2011 Nov; 15(11):e740-6. PubMed ID: 21803628
[TBL] [Abstract][Full Text] [Related]
7. Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea.
Yang SY; Lee HW; Lee YJ; Park SJ; Yoo KY; Kim HJ
Clin Mol Hepatol; 2015 Jun; 21(2):125-30. PubMed ID: 26157749
[TBL] [Abstract][Full Text] [Related]
8. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting.
Desmond CP; Roberts SK; Dudley F; Mitchell J; Day C; Nguyen S; Pianko S
J Viral Hepat; 2006 May; 13(5):311-5. PubMed ID: 16637861
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
[TBL] [Abstract][Full Text] [Related]
11. Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.
Akuta N; Suzuki F; Arase Y; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Ikeda K; Kumada H
Intervirology; 2010; 53(3):188-92. PubMed ID: 20197686
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
Husa P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Urbanek P
Eur J Gastroenterol Hepatol; 2011 May; 23(5):375-81. PubMed ID: 21502923
[TBL] [Abstract][Full Text] [Related]
13. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
[TBL] [Abstract][Full Text] [Related]
14. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
Giannini EG; Basso M; Savarino V; Picciotto A
Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
[TBL] [Abstract][Full Text] [Related]
15. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.
Kim KH; Jang BK; Chung WJ; Hwang JS; Kweon YO; Tak WY; Lee HJ; Lee CH; Suh JI
Korean J Hepatol; 2011 Sep; 17(3):220-5. PubMed ID: 22102389
[TBL] [Abstract][Full Text] [Related]
17. Sustained virological response after treatment in patients with chronic hepatitis C infection--a five year follow up.
Rahman MZ; Ahmed DS; Masud H; Parveen S; Rahman MA; Chowdhury MS; Barua R; Ishaque SM
Bangladesh Med Res Counc Bull; 2013 Apr; 39(1):11-3. PubMed ID: 23923405
[TBL] [Abstract][Full Text] [Related]
18. Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.
Yoshida EM; Sherman M; Bain VG; Cooper CL; Deschênes M; Marotta PJ; Lee SS; Krajden M; Witt-Sullivan H; Bailey RJ; Usaty C; Peltekian K;
Can J Gastroenterol; 2009 Mar; 23(3):180-4. PubMed ID: 19319382
[TBL] [Abstract][Full Text] [Related]
19. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
[TBL] [Abstract][Full Text] [Related]
20. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
Moon C; Jung KS; Kim DY; Baatarkhuu O; Park JY; Kim BK; Kim SU; Ahn SH; Han KH
Dig Dis Sci; 2015 Feb; 60(2):573-81. PubMed ID: 25236421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
